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To the Editor 
 
Myelodysplastic syndromes (MDS) are a heterogeneous and complex group of 
hematopoietic stem cell disorders, primarily found within the elderly 
population, characterized by ineffective hematopoiesis with a variable risk to 
progression to acute myeloid leukemia,. Despite innovative drug 
developments, allogeneic hemopoietic cell transplantation (HCT) is, to date, 
the only available curative option for myelodysplastic syndrome patients [1,2]. 
Indication and timing of the procedure have been widely discussed in the 
literature [3-5]. However, HCT is broadly underutilized: older patients’ age, 
age related comorbidities, lack of appropriate donor are factors involved into 
the limited application of HCT to MDS [6-7]. Over the last decade, the 
emerging role of reduced-intensity conditioning and the use of alternative 
donors (i.e. haplotransplant, cord blood transplant) have expanded the 
eligibility and feasibility of this procedure to several patients and to those who 
are not eligible for a standard myeloablative conditioning regimen. Because a 
haploidentical donor is available in most families recent implementation of 
haploidentical HCT in transplant centers program has offered to many patients 
the opportunity to undergo this potentially curative approach. 
From August 2011 until March 2016, 30 consecutive patients with median age 
of 60 years (range 43-70) and a median comorbidity index [8] of 3 (range 0-
7), underwent T cell replete haplotransplant [9]. All but one presented 
advanced disease characteristics: 16 very high risk , 8 high risk, 5 
intermediate, 1 low risk according the revised international prognostic scoring 
system (r-IPSS)[10].  
Median diagnosis-transplant interval was 9.5 months. Fifteen patients had 
received de-methylating agents before transplant, no complete response was 
observed. Haplo donors/recipients were typed at the HLA-A, HLA-B,HLA-C, 
HLA-DRB1 at high resolution level. The donor/recipient pairs exhibited a 
median of 4 mismatches (range 0 to 4) on the unshared haplotype. 
Conditioning regimen was assigned on the basis of age and comorbidity index 
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[8]:  ten patients received myeloablative conditioning regimen and 20 a 
reduced intensity conditioning regimen as previously reported [9].   
All patients received un-manipulated marrow derived hemopoietic cells. 
Marrow harvest was done as previously described [11].  The median of infused 
nucleated cell dose was 3.1 x108/kg (range 1.1-6). Graft versus host 
prophylaxis was performed by post transplant high doses of cyclophosphamide 
[9]. 
Overall survival, disease free survival rate, non-relapse mortality, acute and 
chronic graft versus host disease (GvHD) rates were calculated using the 
method of Kaplan and Meier with relapse and death as competitive events.  
 
The cumulative incidence of grade II-IV acute GvHD was 15%. Chronic GvHD 
developed in six patients and was extensive in five. Two patients experienced 
graft failure and were successfully re-transplanted with the same haploidentical 
donor after non myeloablative-conditioning regimen. Cumulative incidence of 
non-relapse mortality was 4% and 18% at one and 4 years, respectively. Two 
patients died in complete remission at 389 (chronic GvHD+ sepsis) and 1123 
(interstitial pneumonitis) days after transplant, respectively.  
Seven patients relapsed at a median time from transplant of 188 days (range 
139 - 560 days). Cumulative risk of relapse was 27%. All relapsed patients 
subsequently died by disease progression despite best supportive care (n=4), 
salvage therapy with donor lymphocytes infusion (n=1), de-methylating 
agents and donor lymphocytes infusion (n=1) or acute leukemia like 
chemotherapy plus de-methylating agent and donor lymphocytes infusion (n= 
1). At the time of this writing of the 21 surviving patients (all in remission) two 
are receiving chronic GvHD treatment.  
With a median follow up of 20.5 months (range 4 - 54) the 3 years overall 
survival and disease free survival were 72% (95% CI 63-81) and 69% (95% 
CI 60-78), respectively. Figure 1 reports the 3 years overall (a) and disease 
free survival (b). Relapse remains a major challenge in this setting of patients 
with extremely poor prognosis despite post transplant treatment therapy. No 
significant risk factor for death or relapse was identified in our limited 
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transplant series however mutation analysis was not carried out. A dismal 
outcome has been recently reported in several research articles according to 
somatic mutational status [12.13]. A better relapse risk stratification before 
HCT could help identify subgroups of patients who are more likely to benefit 
from an adapted conditioning regimen or from early post transplant 
therapeutic strategies such as preemptive/prophylactic donor lymphocytes 
infusion and/or hypo-methylating agents. 
This analysis is hampered by the limited number of patients analyzed and by 
the usual limitations related to its retrospective nature. However these data, 
considering very high-risk features of disease in more than 50% of patients 
and elevated median comorbidity index are encouraging and deserve further 
studies. A larger prospective trial of haploidentical transplant in higher risk 
MDS patients fitting with the procedure and lacking an HLA identical donor is 
warranted. 
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Figure legend 
 
Figure 1: Three years overall (a) and disease free survival (b) of the 30 MDS 
patients submitted to haploidentical HCT. Because of the limited number of 
patients in follow up after the third year no survival data have been calculated 
after these limit despite e single late death (day + 1123) was registered.  
 
 
 
 
   
Page 8 of 8
John Wiley & Sons
American Journal of Hematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Three years overall (a) and disease free survival (b) of the 30 MDS patients submitted to haploidentical HCT. 
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